Synaffix expands licensing agreement with MacroGenics

Published: 15-Mar-2023

The expansion comes just a year after the original February 2022 deal, increasing the total potential consideration by up to $2.2 billion

Synaffix has announced the expansion of its licence agreement with biopharmaceutical company MacroGenics.

The expansion comes just a year after the original February 2022 deal, increasing the total potential consideration by up to $2.2 billion, plus tiered low to high single-digit royalties on potential net sales of any resulting products. MacroGenics currently has the option to pursue up to seven ADC programs under the expanded deal, which includes three programs from the original collaboration.

Under the original licensing agreement, MacroGenics gained access to Synaffix’s clinical stage GlycoConnect antibody conjugation technology, HydraSpace polar spacer technology, as well as select toxSYN linker-payloads (SYNtecan E, SYNeamicin D and SYNeamicin G), each designed to enable ADCs with best-in-class efficacy and tolerability. These may be combined with MacroGenics’ proprietary antibody and bispecific DART platform technologies to generate next-generation ADCs.

We look forward to continuing our close collaboration with the talented team at MacroGenics in order to deliver novel therapeutic candidates for patients in need

Anthony DeBoer, Vice President of Business Development at Synaffix, said: “The expansion of our agreement with MacroGenics is a significant milestone for Synaffix that further underscores the growing momentum behind our proprietary ADC technology.  

DeBoer continued: “There are now 13 companies that have publicly disclosed the development of more than 20 ADCs that were built using our technology, with 5 programs that have commenced clinical development to date. We look forward to continuing our close collaboration with the talented team at MacroGenics in order to deliver novel therapeutic candidates for patients in need.”

Ezio Bonvini, M.D., Chief Scientific Officer of MacroGenics, said: “MacroGenics continues to be excited about the promise of Synaffix’s novel drug-linker technology that can help advance multiple potential first and best-in-class ADCs for the treatment of cancer.”

You may also like